The company’s lead compound ricolinostat is an oral, selective inhibitor of the microtubule-modifying enzyme histone deacetylase 6 (HDAC6). With first-in-class potential, ricolinostat is ...

EKZ-102 is in IND-enabling development for the treatment of ALS and other neurodegenerative diseases, with a first-in-human clinical study planned for 2025 ...